- Healthcare Professionals
- Research
- Clinical trials
- 2693-cl-1303
2024-07-30T00:00:00.000+10:00
Ongoing
2693-CL-1303
2693-CL-1303
Breast Cancer
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
Trial overview
Disease
Breast cancer
Topic
Diagnostics
Sponsor
Astellas Pharma
Description
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
Study details
For detailed information on this trial, please click here
Trial status
Opening September 2024
Location
Oxford
:::
Priniciple Investigator
Dr. Rene Roux